REG - Fusion Antibodies - OptiMAL R&D Update

Fusion AntibodiesAnnouncement

31/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250131:nRSe3633Va&default-theme=true

RNS Number : 3633V  Fusion Antibodies PLC  31 January 2025

 

31 January 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

OptiMAL
(http://www.investegate.co.uk/announcement/rns/fusion-antibodies--fab/optimal-collaboration-agreement-/7906203)
(®
(http://www.investegate.co.uk/announcement/rns/fusion-antibodies--fab/optimal-collaboration-agreement-/7906203)
)
(http://www.investegate.co.uk/announcement/rns/fusion-antibodies--fab/optimal-collaboration-agreement-/7906203)
R&D
(http://www.investegate.co.uk/announcement/rns/fusion-antibodies--fab/optimal-collaboration-agreement-/7906203)
Update

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, provides an update on the OptiMAL® validation project being
performed under the collaboration agreement (the "Agreement") with the
National Cancer Institute ("NCI").

 

The validation project is progressing as planned and, using Fusion's OptiMAL®
Library, the NCI has identified a number of antibody expressing cells that
positively bind to their targets of interest.  Fusion will extract and
sequence the DNA encoding for the antibodies from these cells for verification
of binding and further analyses. This analysis will take several months. The
Company has received the first batch of cells from the NCI that have been
isolated from the OptiMAL® Library for this validation work and additional
batches will be shipped subsequently. Fusion is undertaking this work on a
goodwill basis to assist the validation of the OptiMAL® Library. The NCI will
continue the process of identifying more positive cells against their various
targets and the Company also anticipates assisting in the analysis of the
antibodies produced from these cells.

 

NCI, part of the US National Institutes of Health, is the US federal
government's principal agency for cancer research and training. Pursuant to
the Agreement, details of which were announced by the Company on 28 November
2023, Fusion has provided NCI with access to OptiMAL® for use in the
discovery of novel antibodies against targets selected by NCI.

 

Richard Buick, CSO of Fusion Antibodies plc, commented: "We are excited by the
prospect of analysing the antibodies from these OptiMAL® cells selected by
Dr. Mitchell Ho's group at the NCI. The cells have shown positive binding
activity to their target of interest and Fusion will now work on the
validation of the antibody binding. We look forward to assisting the NCI in
the validation of the OptiMAL® platform under the Agreement."

 

Enquiries:

 

 Fusion Antibodies plc                                                          www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                             Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                             Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                          Tel: +44 (0) 207 186 9952

 Walbrook PR                       Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFZGFMRGVGKZM